加拿大卫生部批准Ozempic减少2型糖尿病患者肾衰减。 Health Canada approves Ozempic for reducing kidney decline in Type 2 diabetes patients.

加拿大卫生部已经批准了Ozempic,一种注射药物,以减少2型糖尿病患者的肾衰减。 Health Canada has approved Ozempic, an injectable drug, to reduce kidney decline in patients with Type 2 diabetes. 一项国际试验显示,与安慰剂相比,服用Ozempic的病人肾脏恶化或衰竭的风险低24%。 An international trial showed a 24% lower risk of kidney deterioration or failure in patients taking Ozempic compared to a placebo. 诺沃·诺迪斯克制作的Ozempic也有助于控制血糖和减少食欲,并被批准为Wegovy名下的减重药物。 Ozempic, made by Novo Nordisk, also helps control blood sugar and decrease appetite, and is approved as a weight-loss drug under the name Wegovy. 这使Ozempic成为加拿大第一种保护糖尿病患者肾脏和心脏的GLP-1药物。 This makes Ozempic the first GLP-1 drug in Canada to protect both kidneys and the heart in diabetes patients.